Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC. Rosner S, Forde PM. J Thorac Oncol 2022;17:503-509.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Rosner S, Forde PM. Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC. J Thorac Oncol 2022;17:503-509.
PMID: 35307107